ArticleNeurology2026
Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe brain-predicted age difference (brain-PAD) is considered a marker of neurodegeneration in people with multiple sclerosis (pwMS) and is associated with greater disability and cognitive impairment. However, the impact of disease-modifying factors (DMFs) on brain-PAD remains unknown, as does the extent to which their effect on disability and cognition is mediated through brain-PAD. The goal of this study was to investigate this in pwMS using a same-age cohort to eliminate calendar age as a confounding factor.
methodsBrain age was determined using brainageR from 3-dimensional T1-weighted MRI scans, and brain-PAD was calculated as the difference between predicted and chronological age. Disability was evaluated with the Expanded Disability Status Scale (EDSS), the 9-hole peg test (9HPT), and timed 25-foot walk test (T25FWT). Cognitive function was assessed using the Minimal Assessment of Cognitive Function in MS battery and converted to
resultsThe study included 117 healthy controls (mean age 52.8 ± 1.1 years, 74.3% female) and 242 pwMS (mean age 52.8 ± 0.9 years, 70.6% female), with a median disease duration of 15.2 years (interquartile range [IQR] 8.2-24.5) and a median EDSS score of 3.5 (IQR 2.5-4.0). Smoking (β = 0.20, DISCUSSION: DMFs unrelated to MS, particularly smoking, alcohol use, and BMI at 18 years, accelerate brain aging. Brain-PAD mediates these effects and contributes to worsening disability and cognition, underscoring the potential of lifestyle interventions to mitigate neurodegeneration and preserve function in pwMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.